Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 23.23 [6][5]. Core Views - The company achieved a revenue of RMB 3.398 billion in 2025, representing a year-on-year growth of 10.7%, and a net profit attributable to the parent company of RMB 401 million, up 33.18% year-on-year [1][2]. - The company is optimistic about the future development of its microbial protein project and pet segment, which are expected to provide new growth momentum for high-quality development [1][5]. Revenue Breakdown - The revenue from the biological products segment was RMB 1.475 billion, growing by 11.4% year-on-year, accounting for 43.4% of total revenue [2]. - The pet segment saw significant growth, with revenue reaching RMB 858 million, a year-on-year increase of 24.4% [2]. - The international business segment reported revenue of RMB 127 million, with a year-on-year growth of 33.0% [2]. Profitability Analysis - The gross margin for the biological products business improved by 0.94 percentage points to 63.7%, enhancing overall profitability [3]. - The gross margin for the drug formulation and raw materials segment decreased by 1.34 percentage points to 35.3% due to intensified industry competition [3]. - The company increased its R&D investment, with R&D expenses reaching RMB 253 million, a year-on-year increase of 28.7% [3]. Strategic Initiatives - The company invested RMB 679 million to build a 60,000-ton annual production base for mycelium protein in Tianjin, which is expected to contribute approximately RMB 1.3 billion in annual revenue once fully operational [4]. - The company has obtained 19 new veterinary drug certificates in the pet sector, covering various fields such as deworming and vaccines, and has established a comprehensive supply chain covering over 14,000 medical terminals across 24 provinces [4].

Group 1 - The core viewpoint of the article emphasizes the importance of supporting college students' innovation and entrepreneurship in Changde City, highlighting the establishment of a talent exchange bridge between universities and local industries [2][4]. - The meeting reported on the development of the synthetic biology industry in Changde and the related policies supporting college students' innovation and entrepreneurship [4]. - Representatives from various universities shared their experiences and suggestions for promoting high-quality development in innovation and entrepreneurship [4]. Group 2 - Changde's Mayor, Luo Yijun, expressed a strong desire for young talents and innovation partners, stating that the city is currently pushing for a "second entrepreneurship" with a welcoming environment for startups [5]. - The city is portrayed as a "treasure city" with significant development potential, offering comprehensive support policies for innovation and entrepreneurship [4][5]. - Luo Yijun encouraged participants to consider Changde as a place to plant their creative ideas and projects, aiming for mutual growth and success [5].

Group 1 - The Hangzhou Bay Cross-Sea Railway Bridge has achieved a significant milestone with the completion of the final concrete pouring for the main tower No. 8, which stands at 200 meters, marking the first tower to be topped among the seven main towers of the bridge [2] - The bridge, which is the longest cross-sea railway bridge under construction globally, is part of the new Nantong to Ningbo high-speed railway, an essential component of China's "eight vertical and eight horizontal" high-speed rail network [2] - The bridge's construction faces challenges due to the strong tidal currents and complex navigation environment of the Hangzhou Bay, necessitating a comprehensive safety system involving VTS, CCTV, patrol boats, and drones [2] Group 2 - The Wuxi International Life Science Innovation Park Phase III has been officially completed, covering an area of approximately 100,000 square meters, and is the first specialized park in Wuxi focusing on synthetic biology [4] - The park is designed to facilitate a seamless integration of research, small-scale testing, office, and living spaces, aiming to accelerate the development of the synthetic biology sector, which is projected to be a trillion-dollar industry [4] - The project is located in the Wuxi High-tech Zone and will focus on creating a headquarters research area for synthetic biology, providing quality space for upstream and downstream enterprises in the industry [4]

Group 1 - Nanyang City has launched an action plan to develop a biomanufacturing pilot zone, focusing on project traction, platform construction, and element guarantee to accelerate the transformation and industrial application of scientific research achievements [1] - The Henan Qianmu Biopharmaceutical Project, jointly invested by Qianhong Pharmaceutical and Muyuan Group, has been put into production, filling the gap in high-end heparin raw materials in Henan Province and integrating Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang has 46 biopharmaceutical enterprises above designated size, with an estimated total industry chain output value of approximately 40 billion yuan in 2024, and 25 provincial-level innovation platforms, supporting a full chain from R&D to pilot testing to industrialization [1] Group 2 - Nanyang is actively developing synthetic biology, leveraging the talent and technological advantages of the Nanyang Synthetic Biology Research Institute to create a new generation of efficient, low-consumption, and green bioprocessing platforms [1] - The city is focusing on the industrialization of high-efficiency biosynthesis projects for essential amino acids and microbial synthesis of oils, as well as the development of high-end bio-based materials and new food products like "artificial protein" [1] - The construction of strategic leading laboratories is being strengthened, with the first technology transfer project from the Nanyang pilot base entering mass production, expected to generate an annual output value of about 240 million yuan [2] Group 3 - Nanyang has established a technology innovation system that integrates production, education, research, and application, relying on key research platforms like Muyuan Laboratory and local universities [2] - The city has formed a favorable development pattern characterized by leading enterprises, chain-driven growth, strong product R&D capabilities, and wide market coverage in the biomanufacturing industry [2]

Group 1 - The core viewpoint of the article is that Nanyang City is actively developing a biomanufacturing industry by implementing an action plan that focuses on project traction, platform construction, and element guarantee to transform research achievements into industrial applications [1][2] - The establishment of the Henan Qianmu Biopharmaceutical project, a joint investment by Qianhong Pharmaceutical and Muyuan Group, fills the gap in high-end heparin raw materials in Henan Province and integrates Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang currently has 46 biopharmaceutical enterprises above designated size, with an expected total industry chain output value of approximately 40 billion yuan in 2024 [1] Group 2 - Nanyang is enhancing its strategic laboratory construction, with the Muyuan Laboratory's "one center, one base" development model and the Zhengzhou R&D center operating in an orderly manner [2] - The first technology transfer project from Nanyang's pilot base, the "Muyuan Anliang Isolucine Project," is expected to achieve an annual output value of about 240 million yuan [2] - The city is building a technology innovation system that integrates production, education, research, and application, leveraging the advantages of key research platforms and local universities [2]

Core Viewpoint - In 2024, the company reported its first annual loss since its listing, with a net profit of -56.55 million yuan, attributed to industry adjustments, new capacity investments, and increased expenses [2][5] Financial Performance - Revenue for 2024 was 278 million yuan, a decrease of 20.92% year-on-year [2][12] - The net profit attributable to shareholders was -56.55 million yuan, marking a 309.69% decline compared to the previous year [12] - The company recorded asset impairment losses totaling 34.84 million yuan, with 27.26 million yuan related to accounts receivable [2] Business Operations - The company plans to enhance its cash flow by pursuing legal actions to expedite receivables collection, with accounts receivable amounting to 211 million yuan as of the end of Q1 [2] - The company’s main business includes the production and sale of biological feed products and inorganic solid waste treatment services [2] Strategic Initiatives - The company aims to develop synthetic biology as its third growth curve, focusing on early-stage quality projects through cautious investments [2][7] - The company has rebranded from "Lude Environmental Technology Co., Ltd." to "Lude Biological Environmental Technology Co., Ltd." to reflect its business transformation [5] Market Position and Future Outlook - The biological fermentation feed business generated 217 million yuan in revenue, accounting for 78.11% of total revenue, an increase of 31.80 percentage points from 2022 [5] - The company has expanded its production capacity from one factory to five, with a total capacity of 470,000 tons per year, and plans to increase it to 1 million tons [6][7] - The company expects stable growth in revenue and net profit for 2025, driven by the synthetic biology sector, particularly in beauty and functional food applications [7]